Compare IRON & WLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRON | WLY |
|---|---|---|
| Founded | 2017 | 1807 |
| Country | United States | United States |
| Employees | N/A | 5200 |
| Industry | Biotechnology: Pharmaceutical Preparations | Books |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.1B |
| IPO Year | 2020 | N/A |
| Metric | IRON | WLY |
|---|---|---|
| Price | $80.06 | $50.30 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $103.18 | N/A |
| AVG Volume (30 Days) | ★ 812.9K | 687.6K |
| Earning Date | 05-07-2026 | 06-16-2026 |
| Dividend Yield | N/A | ★ 3.50% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.04 |
| Revenue Next Year | $283.52 | $2.36 |
| P/E Ratio | ★ N/A | $15.84 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $40.00 | $28.38 |
| 52 Week High | $99.50 | $53.24 |
| Indicator | IRON | WLY |
|---|---|---|
| Relative Strength Index (RSI) | 69.40 | 66.16 |
| Support Level | $70.29 | $37.01 |
| Resistance Level | $82.70 | N/A |
| Average True Range (ATR) | 3.14 | 2.31 |
| MACD | 0.81 | 0.53 |
| Stochastic Oscillator | 73.44 | 77.78 |
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
John Wiley & Sons Inc is a publisher and a trusted leader in research and learning. The company segment includes: Research, which includes the reporting lines of Research Publishing and Research Solutions, and Learning includes the Academic and Professional reporting lines and consists of publishing, courseware, and assessments. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.